'Enough is Enough': Sanders Demands Treasury Block Pfizer Tax Dodging Deal
Corporate inversions are 'nothing less than a tax scam,' says Sanders
In a bid to prevent what has been called the biggest tax evasion scheme of its kind--and others like it--Sen. Bernie Sanders of Vermont has urged U.S. Treasury Secretary Jack Lew to use his agency's authority to block the planned merger of two pharmaceutical giants.
Viagra-maker Pfizer's proposal to acquire Allergan, which manufactures Botox, is "nothing less than a tax scam," Sanders wrote in a letter (pdf) sent to Lew on Friday.
The so-called "corporate inversion," which would allow Pfizer to profit from a lower corporate tax rate in Allergan's home country of Ireland, could starve the U.S. government of up to $35 billion in tax revenue, Sanders said, citing a recent report from consumer group Americans for Tax Fairness.
"Enough is enough," Sanders said in a statement on Friday. "Pfizer and other pharmaceutical companies cannot be allowed evade taxes and rip off American patients who already pay the highest prices in the world for prescription drugs."
"The stakes are high," wrote the Democratic presidential candidate. "I find it ironic that some of my Republican colleagues, in their internal budget negotiations, claim that $30 billion in deficit-reduction is required for the coming fiscal year. Preventing the inversion planned by just one company, Pfizer, could produce more deficit-reduction than the cuts they are demanding."
In the absence of Congressional action to limit inversions, Sanders called on the Treasury Department to block tax-dodging techniques like "hopscotch" loans and "earnings stripping"--for Pfizer and other potential corporate tax dodgers, too.
As explained by The Hill:
Hopscotch loans occur when an inverted company moves untaxed overseas profits to U.S. shareholders through transactions that appear to be loans to the foreign parent. Treasury has already blocked hopscotch loans for inverted companies in which at least 60 percent of the merged company is owned by shareholders of the American company, but Pfizer shareholders would only own 56 percent of the combined company after its merger, according to the letter.
Earnings stripping is when U.S. subsidiaries deduct interest payments made to their foreign parents.
The report released last month by Americans for Tax Fairness found that if Pfizer's inversion goes through, the company could avoid paying as much as $35 billion in taxes through such tactics, even while it continues to aggressively raise drug prices.
"By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once," said Americans for Tax Fairness executive director Frank Clemente at the time. "In the company's biggest insult to America yet, Pfizer's merger would allow it to go on enjoying all the benefits of being based here--everything from a publicly-educated workforce, to an excellent communications infrastructure, to a reliable patent system--without adequately paying to support them."
On Thursday, Americans for Tax Fairness delivered more than 270,000 petition signatures to Senate Majority Leader Mitch McConnell, as well as Sens. Richard Durbin (D-Ill.), Jack Reed (D-R.I.), and Elizabeth Warren (D-Mass), calling on Congress to support the Stop Corporate Inversions Act (S. 198).
Sanders' Corporate Tax Dodging Prevention Act (S. 922), introduced last year, also seeks to prevent offshore corporate tax avoidance schemes, including inversions.
Urgent. It's never been this bad.
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission from the outset was simple. To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It’s never been this bad out there. And it’s never been this hard to keep us going. At the very moment Common Dreams is most needed and doing some of its best and most important work, the threats we face are intensifying. Right now, with just three days to go in our Spring Campaign, we're falling short of our make-or-break goal. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Can you make a gift right now to make sure Common Dreams not only survives but thrives? There is no backup plan or rainy day fund. There is only you. —Craig Brown, Co-founder |
In a bid to prevent what has been called the biggest tax evasion scheme of its kind--and others like it--Sen. Bernie Sanders of Vermont has urged U.S. Treasury Secretary Jack Lew to use his agency's authority to block the planned merger of two pharmaceutical giants.
Viagra-maker Pfizer's proposal to acquire Allergan, which manufactures Botox, is "nothing less than a tax scam," Sanders wrote in a letter (pdf) sent to Lew on Friday.
The so-called "corporate inversion," which would allow Pfizer to profit from a lower corporate tax rate in Allergan's home country of Ireland, could starve the U.S. government of up to $35 billion in tax revenue, Sanders said, citing a recent report from consumer group Americans for Tax Fairness.
"Enough is enough," Sanders said in a statement on Friday. "Pfizer and other pharmaceutical companies cannot be allowed evade taxes and rip off American patients who already pay the highest prices in the world for prescription drugs."
"The stakes are high," wrote the Democratic presidential candidate. "I find it ironic that some of my Republican colleagues, in their internal budget negotiations, claim that $30 billion in deficit-reduction is required for the coming fiscal year. Preventing the inversion planned by just one company, Pfizer, could produce more deficit-reduction than the cuts they are demanding."
In the absence of Congressional action to limit inversions, Sanders called on the Treasury Department to block tax-dodging techniques like "hopscotch" loans and "earnings stripping"--for Pfizer and other potential corporate tax dodgers, too.
As explained by The Hill:
Hopscotch loans occur when an inverted company moves untaxed overseas profits to U.S. shareholders through transactions that appear to be loans to the foreign parent. Treasury has already blocked hopscotch loans for inverted companies in which at least 60 percent of the merged company is owned by shareholders of the American company, but Pfizer shareholders would only own 56 percent of the combined company after its merger, according to the letter.
Earnings stripping is when U.S. subsidiaries deduct interest payments made to their foreign parents.
The report released last month by Americans for Tax Fairness found that if Pfizer's inversion goes through, the company could avoid paying as much as $35 billion in taxes through such tactics, even while it continues to aggressively raise drug prices.
"By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once," said Americans for Tax Fairness executive director Frank Clemente at the time. "In the company's biggest insult to America yet, Pfizer's merger would allow it to go on enjoying all the benefits of being based here--everything from a publicly-educated workforce, to an excellent communications infrastructure, to a reliable patent system--without adequately paying to support them."
On Thursday, Americans for Tax Fairness delivered more than 270,000 petition signatures to Senate Majority Leader Mitch McConnell, as well as Sens. Richard Durbin (D-Ill.), Jack Reed (D-R.I.), and Elizabeth Warren (D-Mass), calling on Congress to support the Stop Corporate Inversions Act (S. 198).
Sanders' Corporate Tax Dodging Prevention Act (S. 922), introduced last year, also seeks to prevent offshore corporate tax avoidance schemes, including inversions.
In a bid to prevent what has been called the biggest tax evasion scheme of its kind--and others like it--Sen. Bernie Sanders of Vermont has urged U.S. Treasury Secretary Jack Lew to use his agency's authority to block the planned merger of two pharmaceutical giants.
Viagra-maker Pfizer's proposal to acquire Allergan, which manufactures Botox, is "nothing less than a tax scam," Sanders wrote in a letter (pdf) sent to Lew on Friday.
The so-called "corporate inversion," which would allow Pfizer to profit from a lower corporate tax rate in Allergan's home country of Ireland, could starve the U.S. government of up to $35 billion in tax revenue, Sanders said, citing a recent report from consumer group Americans for Tax Fairness.
"Enough is enough," Sanders said in a statement on Friday. "Pfizer and other pharmaceutical companies cannot be allowed evade taxes and rip off American patients who already pay the highest prices in the world for prescription drugs."
"The stakes are high," wrote the Democratic presidential candidate. "I find it ironic that some of my Republican colleagues, in their internal budget negotiations, claim that $30 billion in deficit-reduction is required for the coming fiscal year. Preventing the inversion planned by just one company, Pfizer, could produce more deficit-reduction than the cuts they are demanding."
In the absence of Congressional action to limit inversions, Sanders called on the Treasury Department to block tax-dodging techniques like "hopscotch" loans and "earnings stripping"--for Pfizer and other potential corporate tax dodgers, too.
As explained by The Hill:
Hopscotch loans occur when an inverted company moves untaxed overseas profits to U.S. shareholders through transactions that appear to be loans to the foreign parent. Treasury has already blocked hopscotch loans for inverted companies in which at least 60 percent of the merged company is owned by shareholders of the American company, but Pfizer shareholders would only own 56 percent of the combined company after its merger, according to the letter.
Earnings stripping is when U.S. subsidiaries deduct interest payments made to their foreign parents.
The report released last month by Americans for Tax Fairness found that if Pfizer's inversion goes through, the company could avoid paying as much as $35 billion in taxes through such tactics, even while it continues to aggressively raise drug prices.
"By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once," said Americans for Tax Fairness executive director Frank Clemente at the time. "In the company's biggest insult to America yet, Pfizer's merger would allow it to go on enjoying all the benefits of being based here--everything from a publicly-educated workforce, to an excellent communications infrastructure, to a reliable patent system--without adequately paying to support them."
On Thursday, Americans for Tax Fairness delivered more than 270,000 petition signatures to Senate Majority Leader Mitch McConnell, as well as Sens. Richard Durbin (D-Ill.), Jack Reed (D-R.I.), and Elizabeth Warren (D-Mass), calling on Congress to support the Stop Corporate Inversions Act (S. 198).
Sanders' Corporate Tax Dodging Prevention Act (S. 922), introduced last year, also seeks to prevent offshore corporate tax avoidance schemes, including inversions.